Skip to main content
Category

Uncategorized

astra zeneca logo

AstraZeneca

By Uncategorized

www.astrazeneca.com

Our scientific heritage is grounded in pushing the boundaries of small molecule discovery and development. For decades, our scientists have led the way in identifying the right chemical leads. Our early discovery and high throughput screening capabilities enable us to screen thousands of compounds a day to identify molecules with potential to inhibit or activate the target.

astra zeneca logo

 

 

 

New Enterprise Associates

By Uncategorized

www.nea.com

As one of the world’s largest and most active venture capital firms, NEA has developed deep domain expertise and insight into our industries of focus. We channel that knowledge into every technology and healthcare investment we make — at any stage, in any location, around the globe.

 

NEAlogo

Montgomery County, MD – Economic Development

By Uncategorized

NewImage

In the 8-0 vote, the Council approved the Plan dubbed “LifeSci Village,” a joint venture of the county and private developer Percontee.  It encompasses 300 acres off Route 29 and Industrial Parkway in the White Oak area of Silver Spring, adjacent to the Food and Drug Administration headquarters.  The development will include housing and retail and will become the newsest hub for medical and life-sciences research in the county.

Image: http://www.choosemontgomerymd.com

Read More
n5-sensors-logo

UMD Spin-Off N5 Sensors Gets a Boost

By Uncategorized

n5-sensors-logoWhat do you need to turn a brilliant idea into a business? “A good morale boost,” says Abhishek Motayed, Founder and President of N5 Sensors, Inc. of Rockville. Motayed had that boost this month when N5 Sensors received two Small Business Innovation Research (SBIR) awards totaling $250,000. The grants came from the Environmental Protection Agency (EPA) and the National Science Foundation (NSF) towards N5 Sensors work developing low-power, computer chip-size benzene, carbon monoxide, and ammonia sensors. A 2012 UMD Invention of Year Award winner, Motayed has kept close contact with the university’s Office of Technology Commercialization (OTC), a crucial participant in the creation of N5 Sensors. “My interactions with OTC were very positive and encouraging. They are very knowledgeable—they knew exactly how to advise me on funding, commercialization, and patenting,” says Motayed.

Read Full Article

strand-logo

Apollo Hospitals Launches Strand’s Clinical Genomic Tests for Personalized Medicine

By Uncategorized

strand-logoApollo Hospitals announced the launch of cutting-edge clinical genomic tests from the Strand Center for Genomics and Personalized Medicine, a part of Strand Life Sciences across its hospital network. These tests in oncology, cardiovascular, heritable eye diseases and rare genetic disorders shall be integrated into clinical practice by Apollo’s subsidiary, Sapien Biosciences in partnership with Strand Life Sciences. These tests, will help doctors diagnose disease more precisely, identify the optimal treatment and monitor disease & treatment course for better outcomes. Genomics is integral to Apollo’s focus on Research and Innovations. Genomic testing involves analyses of patient genomes – genes and sequences of DNA/RNA. The analysis helps create better prognostic tools for improved disease screening and prevention strategies. The patient benefits from optimized clinical care, personalization of treatment & monitoring of outcomes. These tests come with comprehensive pre- & post-test counselling to help the patient & their physicians to integrate the tests results into the clinical care provided. Ms. Sangita Reddy, Joint Managing Director, Apollo Hospitals says,“Apollo has always believed that personalized medicine is the future of healthcare delivery. Our Chairman, Dr. P.C Reddy’s foresight of personalized health is becoming a reality today with the availability of such cutting-edge genomic tests.”

Read Full Article

 

hivemember-small

Benevir taking part in the Hive Accelerator and TEDMED 2014

By Uncategorized

hivemember-small Benevir has been accepted into the Hive program and will be taking part in the TEDMED 2014 convention from September 10-12, 2014 in Washington, DC and San Francisco.

BeneVir’s cancer therapeutic is designed to induce the immune system to recognize and rid the body of two types of tumor cell. The first type is responsive to current immunotherapies, and many patients experience complete remissions. Tumor cells of the second type have evolved to hide from the immune system and are refractory to current immunotherapies. These tumor cells are ultimately responsible for tumor recurrence and poor clinical outcomes. To our knowledge, there is no technology in development that can induce immunity to both types of tumor cell. We feel we have a unique perspective in the emerging field of cancer immunotherapy and that our technology will exhibit enhanced clinical benefit for a wide range of cancer patients.

Read the full interview after the jump!

Read Full Article

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.